<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04451564</url>
  </required_header>
  <id_info>
    <org_study_id>FIBRODOPA TRIAL</org_study_id>
    <nct_id>NCT04451564</nct_id>
  </id_info>
  <brief_title>Understanding and Restoring Dopaminergic Function in Fibromyalgia Patients</brief_title>
  <acronym>FIBRODOPA</acronym>
  <official_title>Understanding and Restoring Dopaminergic Function in Fibromyalgia Patients Using a Mindfulness-based Psychological Intervention: A [18F]-DOPA Positron Emissions Tomography (PET) Study Study Protocol for the FIBRODOPA Study- a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Fribourg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Lausanne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Fribourg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibromyalgia (FM) is a very prevalent and debilitating chronic pain disorder that is&#xD;
      difficult to treat. Mindfulness-based techniques are regarded as a very promising approach&#xD;
      for the treatment of chronic pain and in particular FM. The Mindfulness-Oriented Recovery&#xD;
      Enhancement (MORE) intervention, a mindfulness-based group intervention, has shown beneficial&#xD;
      effects in opioid-treated chronic pain patients, including reduced pain severity, functional&#xD;
      interference, and opioid dosing, by restoring neurophysiological and behavioral responses to&#xD;
      reward. First evidence for a hypodopaminergic state and impaired reward processing in FM have&#xD;
      been reported. However, little is known about its impact on dopamine (DA) function and in&#xD;
      particular with regard to DA responses to monetary reward in FM. The aim of the present study&#xD;
      protocol is to evaluate if MORE is able to restore the DA function in FM patients, in&#xD;
      particular with regard to the DA responses to reward, and to reduce pain and mood complaints&#xD;
      in FM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the present study is a multi-center randomized controlled trial (RCT) with 3 time points:&#xD;
      before the intervention, after completion of the intervention and 3-months after completion&#xD;
      of the intervention. Eighty FM patients will be randomly assigned to either the MORE&#xD;
      intervention (N=40) or to a wait-list control group (N=40). Additionally a comparison group&#xD;
      of healthy women (N=20) will be enrolled. The MORE intervention consists of eight 2-hour long&#xD;
      group sessions administered weekly over a period of 8 weeks. Before and after the&#xD;
      intervention, FM participants will undergo [18F] DOPA Positron Emission Tomography (PET) and&#xD;
      functional magnetic resonance (MR) imaging while performing a monetary reward task. The&#xD;
      primary outcome will be endogeneous DA changes measured with [18F] DOPA PET at baseline,&#xD;
      after the intervention (after 8 weeks for control group), and at 3 months' follow-up.&#xD;
      Secondary outcomes will be (1) clinical pain measures and FM symptoms using standardized&#xD;
      clinical scales 2) functional brain changes 3) measures of negative and positive affect,&#xD;
      stress and reward experience in daily life using the Experience Sampling method (ESM) 4)&#xD;
      biological measures of stress including cortisol and alpha-amylase.&#xD;
&#xD;
      Design: If the findings of this study confirm the effectiveness of MORE in restoring DA&#xD;
      function, reducing pain and improving mood symptoms, MORE can be judged to be a promising&#xD;
      means to improve quality of life in FM patients. The findings of this trial may inform health&#xD;
      care providers about the potential use of the MORE intervention as a possible&#xD;
      non-pharmacological intervention for FM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dopamine response</measure>
    <time_frame>within the second year</time_frame>
    <description>Dopamine response measured with 18F-DOPA as percent Bold signal change Range 0.001 +/-0.009 ml g -1 per min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in pain and clinical related measures</measure>
    <time_frame>within the second year</time_frame>
    <description>measured with the brief pain inventory questionnaire (BPI, Cleeland, 1994) Range: 0-40. 0 corresponds to no interference with pain in daily life and 40 corresponds to maximal interference of pain in daily life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>MORE Mindfulness oriented recovery enhancement group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MORE Mindfulness oriented recovery enhancement group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>wait-list</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mindfulness oriented recovery enhancement</intervention_name>
    <description>8- week psychological program based on mindfulness techniques</description>
    <arm_group_label>MORE Mindfulness oriented recovery enhancement group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fibromyalgia syndrome&#xD;
&#xD;
          -  no psychiatric disorders&#xD;
&#xD;
          -  right handed&#xD;
&#xD;
          -  older than 18 years,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  male sex&#xD;
&#xD;
          -  history of neurological disorders&#xD;
&#xD;
          -  left handed&#xD;
&#xD;
          -  psychiatric disorders&#xD;
&#xD;
          -  current substance or tobacco abuse&#xD;
&#xD;
          -  current and past substance dependence&#xD;
&#xD;
          -  schizophrenia spectrum disorder&#xD;
&#xD;
          -  any other form of chronic pain apart from Fibromyalgia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chantal o Martin Sölch, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Fribourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>katharina Ledermann</last_name>
    <phone>+41765330316</phone>
    <email>katharina.ledermann@unifr.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maya Burckhard</last_name>
    <email>maya.burkhard@unifr.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Fribourg</name>
      <address>
        <city>Fribourg</city>
        <zip>1700</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Katharina ledermann</last_name>
      <phone>+41765330316</phone>
      <phone_ext>+41765330316</phone_ext>
      <email>katharina.ledermann@unifr.ch</email>
    </contact>
    <contact_backup>
      <last_name>Chantal martin Sölch</last_name>
      <email>chantal.martinsoelch@unifr.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 19, 2020</study_first_submitted>
  <study_first_submitted_qc>June 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2020</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dopamine</keyword>
  <keyword>reward</keyword>
  <keyword>F-DOPA</keyword>
  <keyword>mindfulness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

